G1 Therapeutics Alpha and Beta Analysis
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as G1 Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in G1 Therapeutics over a specified time horizon. Remember, high G1 Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to G1 Therapeutics' market risk premium analysis include:
Beta (0.82) | Alpha 1.71 | Risk 0.19 | Sharpe Ratio 0.38 | Expected Return 0.0704 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
GTHX |
G1 Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. G1 Therapeutics market risk premium is the additional return an investor will receive from holding G1 Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in G1 Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate G1 Therapeutics' performance over market.| α | 1.71 | β | -0.82 |
G1 Therapeutics Fundamentals Vs Peers
Comparing G1 Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze G1 Therapeutics' direct or indirect competition across all of the common fundamentals between G1 Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as G1 Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of G1 Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing G1 Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare G1 Therapeutics to competition |
| Fundamentals | G1 Therapeutics | Peer Average |
| Return On Equity | -1.09 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Profit Margin | (0.77) % | (1.27) % |
| Operating Margin | (0.21) % | (5.51) % |
| Current Valuation | 364.46 M | 16.62 B |
| Shares Outstanding | 52.76 M | 571.82 M |
| Shares Owned By Insiders | 10.92 % | 10.09 % |
G1 Therapeutics Opportunities
G1 Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | FY2024 Earnings Forecast for G1 Therapeutics, Inc. Issued By HC Wainwright - Defense World | 06/27/2024 |
2 | Disposition of 57286 shares by Velleca Mark A. of G1 Therapeutics at 1.9986 subject to Rule 16b-3 | 07/26/2024 |
3 | G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 08/01/2024 |
4 | Pharmacosmos Group to Acquire G1 Therapeutics | 08/07/2024 |
5 | G1 Therapeutics Inc Q2 2024 Earnings EPS of Beats Estimates, Revenue of 16. ... | 08/08/2024 |
6 | GTHX SHAREHOLDER ALERT The MA Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc. | 08/09/2024 |
About G1 Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including GTHX or other delisted stocks. Alpha measures the amount that position in G1 Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
G1 Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of G1 Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, G1 Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of G1 Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of G1 Therapeutics. Please utilize our Beneish M Score to check the likelihood of G1 Therapeutics' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with G1 Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |